This transgenic mouse model has the advantage over other ischemic models of ET-1 by regulating expression of ET-1 level endogenously in a specific cell type (endothelial cells) rather than regulating its level by external administration to induce the respective effects under ischemia. This evidence concerns the gene EDN1 and ischemia.